Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial

Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain...

Full description

Saved in:
Bibliographic Details
Published inCurrent controlled trials in cardiovascular medicine Vol. 24; no. 1; p. 449
Main Authors Mitsumoto, Hiroshi, Cheung, Ken, Oskarsson, Björn, Andrews, Howard F, Jang, Grace E, Andrews, Jinsy A, Shah, Jaimin S, Fernandes, Joseph Americo, McElhiney, Martin, Santella, Regina M
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 10.07.2023
BioMed Central
BMC
Subjects
ALS
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - complications
Amyotrophic Lateral Sclerosis - diagnosis
Amyotrophic Lateral Sclerosis - drug therapy
Blood pressure
Care and treatment
Causes of
Complications and side effects
Diabetes
Diabetic neuropathy
Disease
Diuretics
Double-blind studies
Drug Combinations
Drug dosages
Drugs, Chinese Herbal
Humans
Hypokalemia
Informed consent
Kampo
Laboratories
Liver cirrhosis
Muscle Cramp - diagnosis
Muscle Cramp - drug therapy
Muscle Cramp - etiology
Muscle cramps
Muscle pain
Patients
Personalized clinical trial
Potassium
Quality of Life
Randomized Controlled Trials as Topic
Shakuyakukanzoto
Study Protocol
TJ-68
Japan
New York
United States > US
Muscle cramps
Personalized clinical trial
Study protocol
Shakuyakukanzoto
Muscle cramp scale
N-of-1 trials
ALS
Kampo
Randomized controlled study
TJ-68
Online AccessGet full text

Cover

Abstract Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain quality of life. A widely prescribed traditional Japanese (Kampo) medicine against muscle cramps, shakuyakukanzoto (TJ-68), has been studied in advanced liver disease, spinal stenosis, kidney failure, and diabetic neuropathy. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, the rationale of our trial is to investigate the safety and effectiveness of TJ-68 in treating painful and disabling muscle cramps in people with ALS outside of Japan. Accordingly, we are conducting a randomized clinical trial to test the safety and efficacy of TJ-68 in participants with ALS reporting frequent muscle cramps using an innovative, personalized N-of-1 design. If successful, TJ-68 may be used for muscle cramps in a broader population of people with ALS. This is a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study has 85% power to detect a one-point shift on the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity of the Columbia Muscle Cramp Scale (MCS). Secondary outcomes include the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate muscle cramps in rare disorders. If TJ-68 proves safe and efficacious then it may be used to treat cramps in ALS, and help to improve and sustain quality of life. This clinical trial has been registered with ClinicalTrials.gov (NCT04998305), 8/9/2021.
AbstractList INTRODUCTION/AIMSMuscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain quality of life. A widely prescribed traditional Japanese (Kampo) medicine against muscle cramps, shakuyakukanzoto (TJ-68), has been studied in advanced liver disease, spinal stenosis, kidney failure, and diabetic neuropathy. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, the rationale of our trial is to investigate the safety and effectiveness of TJ-68 in treating painful and disabling muscle cramps in people with ALS outside of Japan. Accordingly, we are conducting a randomized clinical trial to test the safety and efficacy of TJ-68 in participants with ALS reporting frequent muscle cramps using an innovative, personalized N-of-1 design. If successful, TJ-68 may be used for muscle cramps in a broader population of people with ALS. METHODSThis is a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study has 85% power to detect a one-point shift on the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity of the Columbia Muscle Cramp Scale (MCS). Secondary outcomes include the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). DISCUSSIONThe study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate muscle cramps in rare disorders. If TJ-68 proves safe and efficacious then it may be used to treat cramps in ALS, and help to improve and sustain quality of life. TRIAL REGISTRATIONThis clinical trial has been registered with ClinicalTrials.gov (NCT04998305), 8/9/2021.
Abstract Introduction/aims Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain quality of life. A widely prescribed traditional Japanese (Kampo) medicine against muscle cramps, shakuyakukanzoto (TJ-68), has been studied in advanced liver disease, spinal stenosis, kidney failure, and diabetic neuropathy. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, the rationale of our trial is to investigate the safety and effectiveness of TJ-68 in treating painful and disabling muscle cramps in people with ALS outside of Japan. Accordingly, we are conducting a randomized clinical trial to test the safety and efficacy of TJ-68 in participants with ALS reporting frequent muscle cramps using an innovative, personalized N-of-1 design. If successful, TJ-68 may be used for muscle cramps in a broader population of people with ALS. Methods This is a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study has 85% power to detect a one-point shift on the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity of the Columbia Muscle Cramp Scale (MCS). Secondary outcomes include the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). Discussion The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate muscle cramps in rare disorders. If TJ-68 proves safe and efficacious then it may be used to treat cramps in ALS, and help to improve and sustain quality of life. Trial registration This clinical trial has been registered with ClinicalTrials.gov (NCT04998305), 8/9/2021.
Abstract Introduction/aims Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain quality of life. A widely prescribed traditional Japanese (Kampo) medicine against muscle cramps, shakuyakukanzoto (TJ-68), has been studied in advanced liver disease, spinal stenosis, kidney failure, and diabetic neuropathy. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, the rationale of our trial is to investigate the safety and effectiveness of TJ-68 in treating painful and disabling muscle cramps in people with ALS outside of Japan. Accordingly, we are conducting a randomized clinical trial to test the safety and efficacy of TJ-68 in participants with ALS reporting frequent muscle cramps using an innovative, personalized N-of-1 design. If successful, TJ-68 may be used for muscle cramps in a broader population of people with ALS. Methods This is a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study has 85% power to detect a one-point shift on the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity of the Columbia Muscle Cramp Scale (MCS). Secondary outcomes include the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). Discussion The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate muscle cramps in rare disorders. If TJ-68 proves safe and efficacious then it may be used to treat cramps in ALS, and help to improve and sustain quality of life. Trial registration This clinical trial has been registered with ClinicalTrials.gov (NCT04998305), 8/9/2021.
Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain quality of life. A widely prescribed traditional Japanese (Kampo) medicine against muscle cramps, shakuyakukanzoto (TJ-68), has been studied in advanced liver disease, spinal stenosis, kidney failure, and diabetic neuropathy. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, the rationale of our trial is to investigate the safety and effectiveness of TJ-68 in treating painful and disabling muscle cramps in people with ALS outside of Japan. Accordingly, we are conducting a randomized clinical trial to test the safety and efficacy of TJ-68 in participants with ALS reporting frequent muscle cramps using an innovative, personalized N-of-1 design. If successful, TJ-68 may be used for muscle cramps in a broader population of people with ALS. This is a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study has 85% power to detect a one-point shift on the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity of the Columbia Muscle Cramp Scale (MCS). Secondary outcomes include the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate muscle cramps in rare disorders. If TJ-68 proves safe and efficacious then it may be used to treat cramps in ALS, and help to improve and sustain quality of life. This clinical trial has been registered with ClinicalTrials.gov (NCT04998305), 8/9/2021.
Introduction/aims Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain quality of life. A widely prescribed traditional Japanese (Kampo) medicine against muscle cramps, shakuyakukanzoto (TJ-68), has been studied in advanced liver disease, spinal stenosis, kidney failure, and diabetic neuropathy. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, the rationale of our trial is to investigate the safety and effectiveness of TJ-68 in treating painful and disabling muscle cramps in people with ALS outside of Japan. Accordingly, we are conducting a randomized clinical trial to test the safety and efficacy of TJ-68 in participants with ALS reporting frequent muscle cramps using an innovative, personalized N-of-1 design. If successful, TJ-68 may be used for muscle cramps in a broader population of people with ALS. Methods This is a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study has 85% power to detect a one-point shift on the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity of the Columbia Muscle Cramp Scale (MCS). Secondary outcomes include the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). Discussion The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate muscle cramps in rare disorders. If TJ-68 proves safe and efficacious then it may be used to treat cramps in ALS, and help to improve and sustain quality of life. Trial registration This clinical trial has been registered with ClinicalTrials.gov (NCT04998305), 8/9/2021. Keywords: Kampo, TJ-68, Shakuyakukanzoto, Muscle cramps, ALS, Personalized clinical trial, N-of-1 trials, Randomized controlled study, Muscle cramp scale, Study protocol
Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date, there are no medications specifically approved for the treatment of muscle cramps. Ameliorating muscle cramps in ALS may improve and sustain quality of life. A widely prescribed traditional Japanese (Kampo) medicine against muscle cramps, shakuyakukanzoto (TJ-68), has been studied in advanced liver disease, spinal stenosis, kidney failure, and diabetic neuropathy. The Japanese ALS Management Guideline mentions TJ-68 for difficult muscle cramps in ALS. Therefore, the rationale of our trial is to investigate the safety and effectiveness of TJ-68 in treating painful and disabling muscle cramps in people with ALS outside of Japan. Accordingly, we are conducting a randomized clinical trial to test the safety and efficacy of TJ-68 in participants with ALS reporting frequent muscle cramps using an innovative, personalized N-of-1 design. If successful, TJ-68 may be used for muscle cramps in a broader population of people with ALS. This is a two-site, double-blind, randomized personalized N-of-1 early clinical trial with TJ-68. At least 22 participants with ALS and daily muscle cramps will receive drug or placebo for 2 weeks (one treatment period) followed by a 1-week washout in a four-period cross-over design. While the primary objective is to evaluate the safety of TJ-68, the study has 85% power to detect a one-point shift on the Visual Analog Scale for Muscle Cramps Affecting Overall Daily Activity of the Columbia Muscle Cramp Scale (MCS). Secondary outcomes include the full MCS score, a Cramp Diary, Clinical Global Impression of Changes, Goal Attainment Scale, quality of life scale and ALS functional rating scale-revised (ALSFRS-R). The study is underway. A personalized N-of-1 trial design is an efficient approach to testing medications that alleviate muscle cramps in rare disorders. If TJ-68 proves safe and efficacious then it may be used to treat cramps in ALS, and help to improve and sustain quality of life.
ArticleNumber 449
Audience Academic
Author Fernandes, Joseph Americo
McElhiney, Martin
Cheung, Ken
Mitsumoto, Hiroshi
Jang, Grace E
Shah, Jaimin S
Andrews, Jinsy A
Oskarsson, Björn
Santella, Regina M
Andrews, Howard F
Author_xml – sequence: 1
  givenname: Hiroshi
  orcidid: 0000-0001-6259-8923
  surname: Mitsumoto
  fullname: Mitsumoto, Hiroshi
  email: hm264@cumc.columbia.edu
  organization: Department of Neurology, Columbia University Irving Medical Center, 710 West 186 St, New York, NY, 10032, USA. hm264@cumc.columbia.edu
– sequence: 2
  givenname: Ken
  surname: Cheung
  fullname: Cheung, Ken
  organization: Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 W 168Th St, New York, NY, 10032, USA
– sequence: 3
  givenname: Björn
  surname: Oskarsson
  fullname: Oskarsson, Björn
  organization: Department of Neurology, Mayo Clinic Jacksonville, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA
– sequence: 4
  givenname: Howard F
  surname: Andrews
  fullname: Andrews, Howard F
  organization: Data Coordinating Center (DCC) at New York State Psychiatric Institute and Columbia University, 722 W 168Th St, New York, NY, 10032, USA
– sequence: 5
  givenname: Grace E
  surname: Jang
  fullname: Jang, Grace E
  organization: Department of Neurology, Columbia University Irving Medical Center, 710 West 186 St, New York, NY, 10032, USA
– sequence: 6
  givenname: Jinsy A
  surname: Andrews
  fullname: Andrews, Jinsy A
  organization: Department of Neurology, Columbia University Irving Medical Center, 710 West 186 St, New York, NY, 10032, USA
– sequence: 7
  givenname: Jaimin S
  surname: Shah
  fullname: Shah, Jaimin S
  organization: Department of Neurology, Mayo Clinic Jacksonville, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA
– sequence: 8
  givenname: Joseph Americo
  surname: Fernandes
  fullname: Fernandes, Joseph Americo
  organization: Department of Neurology, University of Nebraska, 4242 Farnam Street, Suite 650, Omaha, NE, 68198, USA
– sequence: 9
  givenname: Martin
  surname: McElhiney
  fullname: McElhiney, Martin
  organization: Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 722 W 168Th St, New York, NY, 10032, USA
– sequence: 10
  givenname: Regina M
  surname: Santella
  fullname: Santella, Regina M
  organization: Department of Environmental Science, Mailman School of Public Health, Columbia University, 722 W 168Th St, New York, NY, 10032, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37430314$$D View this record in MEDLINE/PubMed
BookMark eNptUttu1DAUjFARbRd-gAdkiZfykOJbnIQXtKq4FFUgQXm2TnzZukrire0gLX_JH-FkS2kRihJHPjMjj2eOi4PRj6YonhN8SkgjXkfCsGAlpvmtOeVl86g4IjWvSkFJdXDv_7A4jvEaY85axp8Uh6zmDDPCj4pfX2HUfnA_jUbaT11vyq53o0ZbE6IfoV8mn0tvS4JUnjgFPUrBzV-PkokJpSuDIliTdghmpk9mTDPAWJvhaoe8RZefStEg60MmG0hu3KBhiqo3SAUYthG5EcGw8yn47ZVTqIdkQtaYIcFHF9HJ-uLbqzcopknv0Db45JXvF0W4VV-O9bR4bKGP5tntuiq-v393efaxvPjy4fxsfVGqSvBUasFN1TWUt0CgrWpTE6O5Bc6YJtrWLW0Y0BZrWzXZG--waEglcJ5g1XXAVsX5Xld7uJbb4AYIO-nByWXDh42EkFw-vmy5oqbTFoPpOLeis5wqWuEGKqKpMVnr7V5rO3WD0SrfX_b-QPThZHRXcuN_SIIZo3Ouq-LkViH4mymnIgcXlel7GI2fosxuBG2FEDP05T_Qaz-FHPWCqhgVjLK_qA1kB260ORlQs6hc15WoK8JqkVGn_0HlR5vBqVxX6_L-AwLdE1QONQZj70wSLOdWy32rZW61XFotm0x6cf967ih_asx-AyAP9jA
CitedBy_id crossref_primary_10_1007_s00415_024_12455_5
Cites_doi 10.1159/000109923
10.1038/nrneurol.2013.203
10.1002/mus.26117
10.1080/21678421.2016.1245755
10.1001/jamapediatrics.2020.5801
10.1201/b17537
10.1186/1751-0759-8-6
10.1142/S0192415X03001144
10.1056/NEJMe1911295
10.1136/bmjopen-2019-036056
10.1016/j.eclinm.2022.101590
10.1080/146608200300079536
10.1002/mus.27091
10.1002/jgf2.302
10.1002/14651858.CD004157.pub2
10.1038/s41598-018-33834-9
10.1016/j.ejpain.2011.04.011
10.1016/S0140-6736(96)91680-3
10.1016/j.clinph.2020.04.005
10.1016/S1474-4422(17)30115-1
10.1016/S1474-4422(14)70129-2
10.1056/NEJMoa1916945
10.1016/j.jns.2011.06.016
10.1162/99608f92.e11adff0
10.1002/mus.21245
10.1038/s41598-018-38182-2
10.1080/21678421.2019.1603310
10.1136/jnnp.70.1.70
10.1212/WNL.0000000000002507
10.1111/ene.13799
10.1002/mus.27569
10.1111/hae.13454
10.1080/17434470410019906
10.1002/ana.22093
10.1136/jnnp.2009.200642
10.1016/j.jep.2012.11.005
10.1159/000093256
10.1176/appi.ajp.2011.10111704
10.1007/BF00313868
10.1002/jps.24596
10.1007/s11418-015-0890-z
10.1002/mus.24892
10.1080/14660820410021249
10.1176/appi.ajp.159.7.1201
10.3109/21678421.2014.942668
10.1002/mus.21213
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7RV
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13063-023-07424-8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Nursing and Allied Health Journals
Health & Medical Complete (ProQuest Database)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Nursing & Allied Health Premium
Access via ProQuest (Open Access)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef

MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1745-6215
EndPage 449
ExternalDocumentID oai_doaj_org_article_94c2ebdf0aeb44f6bf42c2508a51d2ee
A756751376
10_1186_s13063_023_07424_8
37430314
Genre Journal Article
GeographicLocations Japan
New York
United States--US
GeographicLocations_xml – name: Japan
– name: New York
– name: United States--US
GrantInformation_xml – fundername: Tsumura and Company
  grantid: no number
– fundername: ;
  grantid: no number
GroupedDBID ---
-5E
-5G
-A0
-BR
0R~
123
2-G
29Q
2WC
53G
5VS
6PF
7RV
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHYZX
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
EBLON
EBS
ECM
EIF
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
NAPCQ
NPM
O5R
O5S
PGMZT
PIMPY
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
U2A
UKHRP
WOQ
WOW
~8M
AAYXX
CITATION
ABVAZ
AFGXO
AFNRJ
3V.
5GY
7XB
8FK
AHMBA
AZQEC
DWQXO
FRP
K9.
PQEST
PQQKQ
PQUKI
PRINS
XSB
7X8
5PM
ID FETCH-LOGICAL-c564t-d64e5b8249a1a957e71ed4fa433d1df79283a290df58afe4b0681560f790cbba3
IEDL.DBID RPM
ISSN 1745-6215
IngestDate Tue Oct 22 15:12:58 EDT 2024
Tue Sep 17 21:30:15 EDT 2024
Fri Oct 25 04:53:43 EDT 2024
Thu Oct 10 20:45:01 EDT 2024
Thu Feb 22 23:41:06 EST 2024
Wed Nov 13 00:20:15 EST 2024
Thu Sep 12 19:29:32 EDT 2024
Sat Nov 02 12:30:25 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Muscle cramps
Personalized clinical trial
Study protocol
Shakuyakukanzoto
Muscle cramp scale
N-of-1 trials
ALS
Kampo
Randomized controlled study
TJ-68
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-d64e5b8249a1a957e71ed4fa433d1df79283a290df58afe4b0681560f790cbba3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-6259-8923
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332004/
PMID 37430314
PQID 2835326323
PQPubID 44365
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_94c2ebdf0aeb44f6bf42c2508a51d2ee
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10332004
proquest_miscellaneous_2836296664
proquest_journals_2835326323
gale_infotracmisc_A756751376
gale_infotracacademiconefile_A756751376
crossref_primary_10_1186_s13063_023_07424_8
pubmed_primary_37430314
PublicationCentury 2000
PublicationDate 2023-07-10
PublicationDateYYYYMMDD 2023-07-10
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-10
  day: 10
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Current controlled trials in cardiovascular medicine
PublicationTitleAlternate Trials
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References L Lacomblez (7424_CR1) 1996; 347
K Ishiuchi (7424_CR40) 2019; 9
EJ Kasarskis (7424_CR12) 2011; 308
A Al-Chalabi (7424_CR54) 2013; 9
Y Miura (7424_CR29) 1999; 49
M Weber (7424_CR19) 2010; 81
JM Shefner (7424_CR36) 2020; 131
S Paganoni (7424_CR7) 2022; 66
B Oskarsson (7424_CR18) 2018; 58
M Swash (7424_CR23) 2019; 26
KK Lee (7424_CR30) 2011; 15
CE Jackson (7424_CR11) 2009; 39
Writing Group, Edaravone ALS Study Group (7424_CR2) 2017; 16
H Mitsumoto (7424_CR10) 2014; 13
Y Takao (7424_CR27) 2015; 61
M McElhiney (7424_CR43) 2014; 15
T Kumada (7424_CR26) 1999; 15
7424_CR21
S Paganoni (7424_CR5) 2020; 383
MD Weiss (7424_CR22) 2016; 86
J Woodcock (7424_CR50) 2019; 381
7424_CR8
KK Lee (7424_CR31) 2013; 145
7424_CR4
BR Brooks (7424_CR3) 2022; 4
WG Bradley (7424_CR20) 2004; 5
BR Brooks (7424_CR37) 2000; 1
DJ Moser (7424_CR38) 2002; 159
K Rockwood (7424_CR44) 1996; 15
JC Roberts (7424_CR45) 2018; 24
KW Davidson (7424_CR51) 2021; 175
H Okumi (7424_CR25) 2014; 8
S Paganoni (7424_CR6) 2021; 63
O Morinaga (7424_CR39) 2018; 8
7424_CR55
7424_CR52
7424_CR53
PH Gordon (7424_CR42) 2004; 5
JG Rabkin (7424_CR14) 2009; 39
EP Pioro (7424_CR13) 2010; 68
N Kaifuchi (7424_CR32) 2015; 69
H Mitsumoto (7424_CR41) 2019; 20
H Mitsumoto (7424_CR9) 1998
C Sadakane (7424_CR33) 2015; 104
C Jenkinson (7424_CR46) 2001; 70
K Posner (7424_CR47) 2011; 168
7424_CR49
7424_CR48
K Ota (7424_CR24) 2020; 21
SS Gubbay (7424_CR16) 1985; 232
HE Stephens (7424_CR17) 2017; 18
F Hinoshita (7424_CR34) 2003; 31
Societas Neurologica Japonica (7424_CR35) 2013
JB Caress (7424_CR15) 2016; 53
T Hyodo (7424_CR28) 2006; 104
References_xml – start-page: 86
  volume-title: Translation for Practical Guideline for Amyotrophic Lateral Sclerosis (ALS) 2013 5. Symptomatic Treatment CQ5–1: How to deal with pain?
  year: 2013
  ident: 7424_CR35
  contributor:
    fullname: Societas Neurologica Japonica
– volume: 15
  start-page: 330
  issue: 6
  year: 1996
  ident: 7424_CR44
  publication-title: Neuroepidemiology
  doi: 10.1159/000109923
  contributor:
    fullname: K Rockwood
– ident: 7424_CR53
– volume: 9
  start-page: 617
  issue: 11
  year: 2013
  ident: 7424_CR54
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2013.203
  contributor:
    fullname: A Al-Chalabi
– ident: 7424_CR8
– volume: 58
  start-page: 42
  issue: 1
  year: 2018
  ident: 7424_CR18
  publication-title: Muscle Nerve
  doi: 10.1002/mus.26117
  contributor:
    fullname: B Oskarsson
– volume-title: Amyotrophic lateral sclerosis
  year: 1998
  ident: 7424_CR9
  contributor:
    fullname: H Mitsumoto
– volume: 18
  start-page: 32
  issue: 1–2
  year: 2017
  ident: 7424_CR17
  publication-title: Amyotroph Lateral Scler Frontotemporal Degener
  doi: 10.1080/21678421.2016.1245755
  contributor:
    fullname: HE Stephens
– volume: 175
  start-page: 404
  issue: 4
  year: 2021
  ident: 7424_CR51
  publication-title: JAMA Pediatr
  doi: 10.1001/jamapediatrics.2020.5801
  contributor:
    fullname: KW Davidson
– ident: 7424_CR4
– ident: 7424_CR55
  doi: 10.1201/b17537
– volume: 8
  start-page: 6
  issue: 1
  year: 2014
  ident: 7424_CR25
  publication-title: Biopsychosoc Med
  doi: 10.1186/1751-0759-8-6
  contributor:
    fullname: H Okumi
– volume: 31
  start-page: 445
  issue: 3
  year: 2003
  ident: 7424_CR34
  publication-title: Am J Chin Med
  doi: 10.1142/S0192415X03001144
  contributor:
    fullname: F Hinoshita
– volume: 15
  start-page: 499
  year: 1999
  ident: 7424_CR26
  publication-title: J Clin Ther Med
  contributor:
    fullname: T Kumada
– volume: 381
  start-page: 1678
  year: 2019
  ident: 7424_CR50
  publication-title: N Engl J Med
  doi: 10.1056/NEJMe1911295
  contributor:
    fullname: J Woodcock
– ident: 7424_CR48
  doi: 10.1136/bmjopen-2019-036056
– volume: 4
  start-page: 101590
  issue: 52
  year: 2022
  ident: 7424_CR3
  publication-title: eClinicalMedicine
  doi: 10.1016/j.eclinm.2022.101590
  contributor:
    fullname: BR Brooks
– volume: 1
  start-page: 293
  issue: 5
  year: 2000
  ident: 7424_CR37
  publication-title: Amyotroph Lateral Scler Other Motor Neuron Disord.
  doi: 10.1080/146608200300079536
  contributor:
    fullname: BR Brooks
– volume: 63
  start-page: 31
  year: 2021
  ident: 7424_CR6
  publication-title: Muscle Nerve
  doi: 10.1002/mus.27091
  contributor:
    fullname: S Paganoni
– volume: 21
  start-page: 56
  issue: 3
  year: 2020
  ident: 7424_CR24
  publication-title: J Gen Fam Med
  doi: 10.1002/jgf2.302
  contributor:
    fullname: K Ota
– ident: 7424_CR21
  doi: 10.1002/14651858.CD004157.pub2
– volume: 8
  start-page: 15568
  issue: 1
  year: 2018
  ident: 7424_CR39
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-33834-9
  contributor:
    fullname: O Morinaga
– volume: 15
  start-page: 1035
  issue: 10
  year: 2011
  ident: 7424_CR30
  publication-title: Eur J Pain
  doi: 10.1016/j.ejpain.2011.04.011
  contributor:
    fullname: KK Lee
– volume: 347
  start-page: 1425
  issue: 9013
  year: 1996
  ident: 7424_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(96)91680-3
  contributor:
    fullname: L Lacomblez
– volume: 131
  start-page: 1975
  issue: 8
  year: 2020
  ident: 7424_CR36
  publication-title: Clin Neurophysiol
  doi: 10.1016/j.clinph.2020.04.005
  contributor:
    fullname: JM Shefner
– volume: 61
  start-page: E132
  issue: 5
  year: 2015
  ident: 7424_CR27
  publication-title: Kobe J Med Sci
  contributor:
    fullname: Y Takao
– volume: 16
  start-page: 505
  year: 2017
  ident: 7424_CR2
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(17)30115-1
  contributor:
    fullname: Writing Group, Edaravone ALS Study Group
– volume: 13
  start-page: 1127
  issue: 11
  year: 2014
  ident: 7424_CR10
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(14)70129-2
  contributor:
    fullname: H Mitsumoto
– volume: 383
  start-page: 919
  year: 2020
  ident: 7424_CR5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1916945
  contributor:
    fullname: S Paganoni
– volume: 308
  start-page: 155
  issue: 1–2
  year: 2011
  ident: 7424_CR12
  publication-title: J Neurol Sci
  doi: 10.1016/j.jns.2011.06.016
  contributor:
    fullname: EJ Kasarskis
– ident: 7424_CR52
  doi: 10.1162/99608f92.e11adff0
– volume: 39
  start-page: 297
  issue: 3
  year: 2009
  ident: 7424_CR14
  publication-title: Muscle Nerve
  doi: 10.1002/mus.21245
  contributor:
    fullname: JG Rabkin
– volume: 9
  start-page: 1587
  issue: 1
  year: 2019
  ident: 7424_CR40
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-38182-2
  contributor:
    fullname: K Ishiuchi
– volume: 20
  start-page: 328
  issue: 5–6
  year: 2019
  ident: 7424_CR41
  publication-title: Amyotroph Lateral Scler Frontotemporal Degener
  doi: 10.1080/21678421.2019.1603310
  contributor:
    fullname: H Mitsumoto
– volume: 70
  start-page: 70
  issue: 1
  year: 2001
  ident: 7424_CR46
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.70.1.70
  contributor:
    fullname: C Jenkinson
– volume: 86
  start-page: 1474
  issue: 16
  year: 2016
  ident: 7424_CR22
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000002507
  contributor:
    fullname: MD Weiss
– volume: 26
  start-page: 214
  issue: 2
  year: 2019
  ident: 7424_CR23
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13799
  contributor:
    fullname: M Swash
– volume: 66
  start-page: 136
  issue: 2
  year: 2022
  ident: 7424_CR7
  publication-title: Muscle Nerve
  doi: 10.1002/mus.27569
  contributor:
    fullname: S Paganoni
– volume: 24
  issue: 4
  year: 2018
  ident: 7424_CR45
  publication-title: Haemophilia
  doi: 10.1111/hae.13454
  contributor:
    fullname: JC Roberts
– volume: 5
  start-page: 90
  issue: Suppl 1
  year: 2004
  ident: 7424_CR42
  publication-title: Amyotroph Lateral Scler Other Motor Neuron Disord
  doi: 10.1080/17434470410019906
  contributor:
    fullname: PH Gordon
– volume: 68
  start-page: 693
  issue: 5
  year: 2010
  ident: 7424_CR13
  publication-title: Ann Neurol
  doi: 10.1002/ana.22093
  contributor:
    fullname: EP Pioro
– volume: 81
  start-page: 1135
  year: 2010
  ident: 7424_CR19
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.2009.200642
  contributor:
    fullname: M Weber
– volume: 145
  start-page: 286
  issue: 1
  year: 2013
  ident: 7424_CR31
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2012.11.005
  contributor:
    fullname: KK Lee
– volume: 49
  start-page: 865
  issue: 5
  year: 1999
  ident: 7424_CR29
  publication-title: Japanese J Orient Med
  contributor:
    fullname: Y Miura
– volume: 104
  issue: 1
  year: 2006
  ident: 7424_CR28
  publication-title: Nephron Clin Pract
  doi: 10.1159/000093256
  contributor:
    fullname: T Hyodo
– volume: 168
  start-page: 1266
  issue: 12
  year: 2011
  ident: 7424_CR47
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2011.10111704
  contributor:
    fullname: K Posner
– volume: 232
  start-page: 295
  issue: 5
  year: 1985
  ident: 7424_CR16
  publication-title: J Neurol
  doi: 10.1007/BF00313868
  contributor:
    fullname: SS Gubbay
– volume: 104
  start-page: 3952
  issue: 11
  year: 2015
  ident: 7424_CR33
  publication-title: J Pharm Sci
  doi: 10.1002/jps.24596
  contributor:
    fullname: C Sadakane
– volume: 69
  start-page: 287
  issue: 3
  year: 2015
  ident: 7424_CR32
  publication-title: J Nat Med
  doi: 10.1007/s11418-015-0890-z
  contributor:
    fullname: N Kaifuchi
– volume: 53
  start-page: 513
  issue: 4
  year: 2016
  ident: 7424_CR15
  publication-title: Muscle Nerve
  doi: 10.1002/mus.24892
  contributor:
    fullname: JB Caress
– volume: 5
  start-page: 240
  issue: 4
  year: 2004
  ident: 7424_CR20
  publication-title: Amyotroph Lateral Scler Other Motor Neuron Disord
  doi: 10.1080/14660820410021249
  contributor:
    fullname: WG Bradley
– ident: 7424_CR49
– volume: 159
  start-page: 1201
  issue: 7
  year: 2002
  ident: 7424_CR38
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.159.7.1201
  contributor:
    fullname: DJ Moser
– volume: 15
  start-page: 398
  issue: 5–6
  year: 2014
  ident: 7424_CR43
  publication-title: Amyotroph Lateral Scler Frontotemporal Degener
  doi: 10.3109/21678421.2014.942668
  contributor:
    fullname: M McElhiney
– volume: 39
  start-page: 137
  issue: 2
  year: 2009
  ident: 7424_CR11
  publication-title: Muscle Nerve
  doi: 10.1002/mus.21213
  contributor:
    fullname: CE Jackson
SSID ssj0043934
ssj0017864
Score 2.384498
Snippet Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative disorder. To date,...
Abstract Introduction/aims Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable...
Introduction/aims Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative...
Introduction/aimsMuscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative...
INTRODUCTION/AIMSMuscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable neurodegenerative...
Abstract Introduction/aims Muscle cramps are a common and often disabling symptom in amyotrophic lateral sclerosis (ALS), a devastating and incurable...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 449
SubjectTerms ALS
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - complications
Amyotrophic Lateral Sclerosis - diagnosis
Amyotrophic Lateral Sclerosis - drug therapy
Blood pressure
Care and treatment
Causes of
Complications and side effects
Diabetes
Diabetic neuropathy
Disease
Diuretics
Double-blind studies
Drug Combinations
Drug dosages
Drugs, Chinese Herbal
Humans
Hypokalemia
Informed consent
Kampo
Laboratories
Liver cirrhosis
Muscle Cramp - diagnosis
Muscle Cramp - drug therapy
Muscle Cramp - etiology
Muscle cramps
Muscle pain
Patients
Personalized clinical trial
Potassium
Quality of Life
Randomized Controlled Trials as Topic
Shakuyakukanzoto
Study Protocol
TJ-68
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQHhAXxJssCxokJEDI2jxs1-FWEKvVit0D7Ep7s-zY1lZqk6pJD-Vf8o8YO0nViAMXDr10JpHt-TwPZfyZkHd5UVgnJZapqfSUmSyjkueWaiGk1JVm3IWDwpdX4vyGXdzy24OrvkJPWE8P3C_cacmq3BnrU-0MY14Yz_IK47bUPLO5c9H7puVYTPU-GKNswcYjMlKctuip4_dK_GEtyKichKHI1v-3Tz4IStOGyYMIdPaIPBxSR5j3Q35M7rn6Cbl_OXwcf0p-_9C1bVaLX86CbbZm6ajBJNLCeky4g-SKNp5mMJ6IhHhtB3QNYM7ZAaaD0Grvuh3o8GTThW4iVHCBakJXO2g8XF9QIQGzXYht6hj8YLVtcUxQbfRq3cKiBr3aNd2mWd8tKljqcMx5CUEFV2PRwof5958fP0PktoVAFdEgHuMb9fD2OKxn5Obs2_XXczrc2EArLlhHrWCOG4klnc50yWduljnLvGaIiMz6WYnJjM7L1HoucS7MpCKw1aQoSStjdPGcHNVN7V4SqKyRzmNyUnnBTD7TlnOLALDolExZ2oR8Gg2o1j0xh4oFjRSqN7dCc6tobiUT8iXYeK8ZSLXjHwg1NUBN_QtqCXkfEKLC1kcY4KL3JxhwwIFES81nHMuvDF12Qk4mmrhlq6l4xJgaXEarAvFdEdjzi4S83YvDk6ENrnbNNuqIHAtUwRLyoofkfkoF5oLhLoKEyAlYJ3OeSurFXSQUz9KiCN7y-H-s0ivyIO83Gob4E3LUbbbuNSZunXkT9-gfzqVETQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Complete (ProQuest Database)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkRAXxJvAgoyEBAhZm4fjOFxQQaxWK3YPsCv1ZvnJVmrj0qSH8i_5R4ydpGyExKGXeJLamfHMN_E8EHqdF4WxnIObmnJHqMoywsvcEMkY51JLWtqQKHx2zk4u6em8nA8f3NohrHLUiVFRG6_DN_KjUBesCMXFi4_rnyR0jQqnq0MLjZvoVpanLIR0VfO9w5VVnNExUYazoxb0dTy1hB94hJTwiTGKNfv_1czXTNM0bPKaHTq-h-4OABLPeo7fRzds8wDdPhuOyB-i399kY_xq8csabPxWLS1RACUNXo-wO4ycE-9Ihse8SBybd-DOY0CeHQZQiFvpbLfDMtzpuxBTBAQ2FJyQeoe9wxenhHEMmBfHYHUwgXi1bWFOWG_kat3iRYPlaue7jV9fLTReypDsvMSBBN7GosVvZ1-_v_uAY4VbHApGeJDK-EQ5PD1O6xG6PP5y8fmEDH0biC4Z7Yhh1JaKg2MnM1mXla0ya6iTFOQiM66qgZcyr1PjSg5roQo4FxK6YSTVSsniMTpofGOfIqyN4tYBRNGOUZVX0pSlodQZUE2qrk2C3o8MFOu-PIeIbg1nome3AHaLyG7BE_Qp8HhPGUprxwt-80MMO1XUVOdWGZdKq-CfmHI01wAUuSwzk1uboDdBQkRQACAG8NL7PAaYcCilJWZVCU5YBoo7QYcTSti4ejo8ypgYFEcr_op5gl7th8OdIRiusX4baVgObiqjCXrSi-R-SQUgwtCRIEF8IqyTNU9HmsVVLCuepUURdOaz_8_rObqT91sITPghOug2W_sCgFmnXsbd9wf8HTpC
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1baxQxFA61QumLeHe0yhEEFRmdSyabEURWsZRi-6At9C0kk8Qu7E7WnVlw_Zf-I08yM0sH68O-zDnJJjl3knwh5EWW59pwjmVqwm1MVZrGvMh0LBnjXFaSFsZfFD45ZUfn9PiiuNghw3NH_QI215Z2_j2p89X87a-fm49o8B-CwXP2rkE_HHYj8YeVHo35DXIzo1ip-6N8dLurgLE3p8PFmWvb7ZO9HEOqh3QfxakA5_-v074StcYnKq-EqMPb5FafW8K0U4Y7ZMfUd8neSb97fo_8-SZr7Raz30aDdms1N7HCLFPDcsjIPeU0djZOYbgyCeFdD2gdYFLaAuaL0Ehr2g1I39K1_rgRMhiPRSGrDTgLZ8cx44DpMIRz7BgdYbFucExQreRi2cCsBrnYuHbllpezCubS34Oeg2fB1Zg18Gr69fvr9xDAb8FjSThU2NCj7HsPw7pPzg-_nH0-ivsnHeKqYLSNNaOmUBxrPpnKspiYSWo0tRKFpVNtJyVmOzIrE20LjnOhKmEeziZBSlIpJfMHZLd2tXlEoNKKG4vZS2UZVdlE6qLQlFqNXkuVpY7Im0GAYtkhd4hQ8XAmOskLlLwIkhc8Ip-8jLecHnU7fHCrH6I3YlHSKjNK20Qahf_ElKVZhTkkl0WqM2Mi8tJriPDaimqAi95dccABe5QtMZ0UWJ-l6NMjcjDiRJuuxuRBx8RgEsIj4-UeXj-PyPMt2bf05-Rq49aBh2VYwTIakYedSm6nNGh2RPhIWUdzHlPq2WVAHE-TPPfu9PF_O31C9rPOkDCwH5DddrU2TzFda9WzYIN_ASY-PTc
  priority: 102
  providerName: Scholars Portal
Title Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial
URI https://www.ncbi.nlm.nih.gov/pubmed/37430314
https://www.proquest.com/docview/2835326323
https://search.proquest.com/docview/2836296664
https://pubmed.ncbi.nlm.nih.gov/PMC10332004
https://doaj.org/article/94c2ebdf0aeb44f6bf42c2508a51d2ee
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZtB2MvY_d564IGg20MN77Isry3tLSUsITSC-TN6ObWEFshdh6yf7l_tCM5DjV720MSiI4cyef2nficI4S-RHGsNGMQpgas8IkIQ58lkfI5pYxxyUmibaHwbE4v78h0kSwOEO1rYVzSvhTlSb2sTuryweVWrio57vPExlezszCIY8vd8SE6BAntY_TO_oKHjUlfHsPouAEr7Z5VwgviQOKzgQtynfr_tcePHNIwWfKR97l4gZ7vYCOedMt7iQ50_Qo9ne0ejL9Gf655rUxV_tYKK7MRS-0LAJAKr3qwbUfmvin8EPfVkNgd2YFbgwFvthigIG54odst5namaW0mERBo22aCyy02Bb6d-pRhQLrYpaiD48PVpoE1Ybnm1arBZY15tTXt2qweSomX3JY4L7ElgbtRNvjb5NfN95_Y9bXFtk2EAVl0V-S7q7tlvUF3F-e3Z5f-7rQGXyaUtL6iRCeCQTjHQ54lqU5DrUjBCUhDqIo0AyDDoyxQRcJgL0QE1HaqCWAkkELw-C06qk2t3yMslWC6AGAiC0pElHKVJIqQQoFBElmmPPSjZ2C-6ppy5C6YYTTv2J0Du3PH7px56NTyeE9pG2q7L8z6Pt-JVZ4RGWmhioBrAb9ERUEiCfCQ8SRUkdYe-molJLdqD2IAN72rXoAF2wZa-SRNIPQKwVx76HhACeoqh8O9jOU7c9HktuldbDvnxx76vB-2M20KXK3NxtHQCIJTSjz0rhPJ_ZZiwIH2HAIPsYGwDvY8HAHdcs3Ee1368P9TP6JnUade4NSP0VG73uhPANVaMQL9XKQj9GQymd5M4fP0fH51PXJ_fMD7jLCR092_xW1HpA
link.rule.ids 230,315,730,783,787,867,888,2109,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806,74073,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkYAL4rkEFjASEiBkbR6O43BBBbEqS9sDdKXeLDt22EptXJr0UP4l_4ixk5SNkDj0knFSOzOe-Sa2v0HoVZwk2nAOaWrIS0JVFBGexppIxjiXhaSpcQeFpzM2vqDni3TRfXCru22VvU_0jlrbwn0jP3W8YIkjF08-bH4SVzXKra52JTSuoxuOh8tVMMgWh4Qryjij_UEZzk5r8Nd-1RJ-kBFSwgfByHP2_-uZr4Sm4bbJK3Ho7C660wFIPGo1fg9dM9V9dHPaLZE_QL-_yUrb9fKX0VjbnVoZogBKarzpYbeTzIgtSYT7c5HYF-_AjcWAPBsMoBDXsjTNHkt3p23cniJoYBzhhCz22JZ4fk4Yx4B5sd-sDiEQr3c19AkXW7ne1HhZYbne22ZrN5fLAq-kO-y8wq4JvI1ljd-MJt_fvsee4RY7wggLVumfKLun-249RBdnn-efxqSr20CKlNGGaEZNqjgkdjKSeZqZLDKalhJUpCNdZjnoUsZ5qMuUw1ioCpnjrAlBEhZKyeQROqpsZR4jXGjFTQkQpSgZVXEmdZpqSksNrknluQ7Qu16BYtPScwif1nAmWnULULfw6hY8QB-djg8tHbW2v2C3P0Q3U0VOi9goXYbSKPgnpkoaFwAUuUwjHRsToNfOQoRzAGAG8NLbcwzQYUelJUZZCklYBI47QCeDljBxi6G4tzHROY5a_DXzAL08iN2dbjNcZezOt2ExpKmMBui4NcnDkBJAhK4iQYD4wFgHYx5KquWlpxWPQphC4DOf_L9fL9Ct8Xw6EZMvs69P0e24nU4Qzk_QUbPdmWcA0hr13M_EP86mPSk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkVZcEO8NLGAkJEDIah6O43BB5VEty26FYFfam2XHNlupjUuTHsq_5B8xdtKyERKHXDpOYmfGM9_U488IvUizTBvOIU2NuSVUJQnheaqJZIxzWUmaG79R-HTKjs7p8UV-0dc_NX1Z5dYnBketXeX_Ix95XrDMk4tnI9uXRXz9OHm3_En8CVJ-pbU_TuM6ulFAluJtvrjYJV9JwRndbprhbNSA7w4rmHBBdkgJHwSmwN__r5e-EqaGJZRXYtLkNrrVg0k87rR_B10z9V20f9ovl99Dv7_JWrvF7JfRWLu1mhuiAFZqvNxCcC-ZEmdJgrd7JHE4yAO3DgMKbTEARNxIa9oNlv5O1_r6ImhgPPmErDbYWXx2TBjHgH9xKFyHcIgX6wb6hKuVXCwbPKuxXGxcu3LLy1mF59JvfJ5j3wS-xqzBr8Yn31-_xYHtFnvyCAcWGp4o-6eHbt1H55NPZx-OSH-GA6lyRluiGTW54pDkyUSWeWGKxGhqJQUbSbQtStCrTMtY25zDWKiKmeeviUESV0rJ7AHaq11tDhCutOLGAlypLKMqLaTOc02p1eCmVFnqCL3ZKlAsO6oOEVIczkSnbgHqFkHdgkfovdfxrqWn2Q4_uNUP0c9aUdIqNUrbWBoFb2LK0rQC0MhlnujUmAi99BYivDMAM4CP3u1pgA57Wi0xLnJIyBJw4hE6HLSESVwNxVsbE70TacRfk4_Q853Y3-kL42rj1qENSyFlZTRCDzuT3A0pA3ToTyeIEB8Y62DMQ0k9uwwU40mcZd5_Pvp_v56hfZiE4uTz9MtjdDPtZhNE9kO0167W5gngtVY9DRPxD7jRQWE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+double-blind+personalized+N-of-1+clinical+trial+to+test+the+safety+and+potential+efficacy+of+TJ-68+for+treating+muscle+cramps+in+amyotrophic+lateral+sclerosis+%28ALS%29%3A+study+protocol+for+a+TJ-68+trial&rft.jtitle=Trials&rft.au=Mitsumoto%2C+Hiroshi&rft.au=Cheung%2C+Ken&rft.au=Oskarsson%2C+Bj%C3%B6rn&rft.au=Andrews%2C+Howard+F&rft.date=2023-07-10&rft.eissn=1745-6215&rft.volume=24&rft.issue=1&rft.spage=449&rft_id=info:doi/10.1186%2Fs13063-023-07424-8&rft_id=info%3Apmid%2F37430314&rft.externalDocID=37430314
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon